YES, WE CAN
Our goal is simple, to improve lives by increasing access to medicines around the world.
We deliver solutions for organizations in the global healthcare network, removing barriers and implementing programs so they can:
- Provide access to medicines for patients in need
- Demonstrate the value of new medications
- Enable better health
YES, WE WILL
Our commitment is unwavering.
We relentlessly pursue and deliver the best solutions to enable access, no matter how challenging the situation. We are resourceful and creative and always going the extra mile.
YES, WE DID
Reduce the risk of infection in leukemia patients.
LEUKINE®, approved by the US FDA in 1991, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
In 2018, Partner Therapeutics, Inc. (PTx) acquired the global rights to develop, manufacture, and commercialize Leukine ® (sargramostim) from Sanofi. As a small company, Ptx did not have the internal resources to handle international requests for the drug and didn’t know how they could successfully support patients outside the US, in full regulatory compliance, even though the product was not registered in other geographies.
YES, WE DID
Provide free cancer treatment to patients around the world
The Max Foundation is a global non-profit organization focused on increasing the access to treatment, care and support for people living with cancer around the world. In 2017 the Foundation sought to put in place The Max Access Solutions program, a patient-centric care model for delivering free cancer treatment to those in need. The Foundation wanted to be able to offer its patients targeted treatment using a portfolio of oncology medicines from multiple pharmaceutical companies. They sought a partner to handle the distribution, quality assurance and regulatory activities to safely and securely store, handle and deliver the medicines to their patients. After evaluating options for a partner to manage the distribution, Tanner was selected.Read More
YES, WE DID
Uninterrupted distribution to patients in Latin America
A major pharmaceutical company divested a mature pipeline asset to a medium size pharma company that did not have a presence in Latin America, but wanted to continue distribution of the product.Read More
YES, WE DID
Assuring continuity during a global pandemic
A leading clinical-stage biotechnology company required packs of a comparator to conduct a Phase III trial for their leading asset. They required the stock in a single lot, and because of the ongoing COVID-19 pandemic, wanted stock with a long shelf life and additional assurances regarding the supply chain to minimize lead times and the chance of unexpected manufacturer disruptions.Read More
Tanner Pharma Group is truly an example of what it means to put humanity at the center of their business. This was not just words on a page or some empty mission statement, it’s compassion in action!
They are a prime example on how Pharma should be running their business and focusing their motivation.Joshua Frase Foundation
PROVIDING ACCESS TO
countries with the help of our non-profit collaborators:
RECENT NEWS & EVENTS
Tanner Pharma Group will be considered in two categories as part of the the Supply Chain Excellence Awards 2022 alongside partners Akeso & Company and Kuehne+Nagel for their collaborative efforts supporting immediate COVID response. Learn more about these two categories below: The Healthcare & Pharmaceutical Supply Chain Excellence Award – Private Sector This award looks to recognize techniques, projects…Read More
Steve Scalia, president of Tanner Pharma Group, was recently interview by Julio Martinez-Clark, founder and producer of the LATAM MedTech Leaders podcast series and CEO of Bioaccess. TannerLAC, a division of Tanner Pharma, provides pharmaceutical, biotech and healthcare companies with a single partner for the licensing, registration and commercialization of specialty pharmaceuticals, supplements and devices…Read More
SUZHOU, China and ROCKVILLE, Md. and CHARLOTTE, N.C./PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Tanner Pharma Group (“Tanner Pharma”), a global pharmaceutical services provider of specialty access solutions, have jointly launched an innovative Named Patient Program (NPP) for olverembatinib. This collaboration will allow access to Ascentage Pharma’s novel…Read More
Max Global Experience: Uganda
Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s 2018 “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.